Abstract 3537
Background
CareAcross is a digital platform dedicated to support, inform and engage with cancer patients. It also collects medical and other data, and generates real world evidence.
Methods
In an effort to collect and analyze information from breast cancer patients regarding side effects in relation to their treatments and supplements intake, we contacted 5373 patients in the UK, Germany, France, Spain and Italy. 547 had triple negative breast cancer (TNBC) and the remaining 4826 had other breast cancer subtypes (non-TNBC). All data was collected anonymously, with strong privacy and security controls.
Results
Different regimens were given as adjuvant or as systemic treatments. AC treatment was given to 10% of TNBC vs 5% of non-TNBC patients; FEC-T to 18% vs 11%, FEC to 9% vs 7%, taxanes to 39% vs 22% and platinum-based chemotherapy to 14% vs 2%, respectively. Among non-TNBC patients, 12% received Trastuzumab and 52% received hormonal treatment. Some of the patients were asked regarding side effects as well as vitamins and supplements intake. Among them, 136 TNBC patients reported an average of 3.0 side effects (95% CI 2.6-3.5), 22% more than those reported by 1015 non-TNBC patients (2.5 side effects; 95% CI 2.4-2.6); p = 0.03. Similarly, an average of 3.6 vitamins and supplements was reported by 111 TNBC patients (95% CI 2.9-4.3), 15% more compared to 854 non-TNBC patients (3.1 supplements; 95% CI 2.9-3.3); p = 0.22. An analysis of the patients reporting at least 1 side-effect showed 120 TNBC patients with an average of 3.5 side effects (95% CI 3.0-3.9), 17% more than 862 non-TNBC patients (3.0 side effects, 95% CI 2.8-3.1); p = 0.05. Regarding consumption of at least 1 vitamin/supplement, the average intake across 85 TNBC patients was 4.7 (9.5% CI 3.9-5.5), 23% more than 697 non-TNBC patients (3.8 vitamins/supplements, 95% CI 3.5-4.0); p = 0.04.
Conclusions
The real world evidence obtained through an international analysis shows that TNBC patients receive more toxic treatments due to the aggressive disease, as expected. TNBC patients experience significantly more side effects compared to non-TNBC patients. They also consume more vitamins and supplements; the difference across patients reporting at least one vitamin/supplement was larger and statistically significant.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Care Across Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3409 - Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer
Presenter: Toshihiko Iuchi
Session: Poster Display session 1
Resources:
Abstract
3683 - Impact of Radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC
Presenter: Evangeline Samuel
Session: Poster Display session 1
Resources:
Abstract
3924 - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real World Data from a European Cohort with focus on subgroups of interest
Presenter: Giannis Mountzios
Session: Poster Display session 1
Resources:
Abstract
3970 - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Martin Sebastian
Session: Poster Display session 1
Resources:
Abstract
5350 - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Presenter: Motohiro Tamiya
Session: Poster Display session 1
Resources:
Abstract
3832 - Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)
Presenter: Giulio Metro
Session: Poster Display session 1
Resources:
Abstract
4082 - Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)
Presenter: Riyaz Shah
Session: Poster Display session 1
Resources:
Abstract
2855 - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumor DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global Ph3 study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations
Presenter: Kazuto Nishio
Session: Poster Display session 1
Resources:
Abstract
2911 - Apatinib combined with EGFR - TKI in treating advanced non-small cell lung cancer with EGFR - TKI resistance
Presenter: Ruifen Tian
Session: Poster Display session 1
Resources:
Abstract
2100 - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
Presenter: Takashi Ninomiya
Session: Poster Display session 1
Resources:
Abstract